Chemomab Q2: Going Concern Warning, Merger Progress, and Phase 2 RA Trial Details
CMMB sits 54% above its 52-week low of $1.35 on light trading volume (0.1× avg).
Summary
Chemomab reported Q2 2026 results with a going concern warning, $6.7M cash, and detailed plans for its Scipher merger and Phase 2 RA trial.
Key Events · Earnings and Guidance · CMMB
-
Going Concern Warning
Cash of $6.7M as of June 30, 2026, funds operations only through Q1 2027. Management states substantial doubt about ability to continue as a going concern.
-
Merger Progress
Confidentially submitted draft Form S-4 to SEC. Merger with Scipher expected to close in Q4 2026, subject to approvals.
-
Phase 2 RA Trial Design
Planned 140-patient trial (35 placebo, 35 nebokitug 10 mg/kg, 70 nebokitug 20 mg/kg) with ACR20 primary endpoint. IND submission in 2026, recruitment start H1 2027, data readout H1 2028.
-
Financial Results
Q2 2026 net loss of $2.2M, R&D expenses of $1.1M, G&A of $1.1M. Six-month net loss of $3.9M.
Analysis · CMMB · Life Sciences
Chemomab's Q2 2026 filing reveals a going concern warning with only $6.7M in cash, enough to fund operations through Q1 2027. The company has confidentially submitted its Form S-4 for the Scipher merger and expects closing in Q4 2026. The combined company plans a Phase 2 RA trial for nebokitug with data expected in H1 2028. The going concern language is a critical red flag for a company with a market cap of only $13.8M, and the merger is the primary path to survival.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMMB was trading at $2.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $1.35 to $4.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.